Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 13/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241285 | 0.94 | ADORA2A (0.58) | ADORA2AADORA3ADORA1NT5EADORA2B | |
| SCHEMBL4116622 | 0.90 | ADORA2A (0.62) | ADORA2AADORA3ADORA1ADORA2B | |
| Hydrochloric Acid SCHEMBL242757 | 0.89 | ADORA2A (0.61) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL1844827 | 0.84 | ADORA2A (0.57) | ADORA2AADORA3ADORA1NT5E | |
| SCHEMBL242820 | 0.84 | ADORA2A (0.57) | ADORA2AADORA3ADORA1NT5E | |
| SCHEMBL243047 | 0.84 | ADORA2A (0.60) | ADORA2AADORA3ADORA1 | |
| SCHEMBL1412152 | 0.84 | ADORA2A (0.70) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL239165 | 0.84 | ADORA2A (0.70) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL1412300 | 0.84 | ADORA2A (0.70) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL1412298 | 0.84 | ADORA2A (0.70) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | ADORA2A 2741/4885ADORA3 795/4885ADORA1 1271/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | ADORA2A 2741/4885ADORA3 795/4885ADORA1 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.